Claims

1. The use of meloxicam or a pharmacologically acceptable salt thereof for the manufacture of a medicament for the long-term treatment of musculoskeletal disorders in cats, characterised in that the treatment occurs over a long-term period of from 13 to 40 months and in that the daily dose of from 0.05 to 0.075 mg/kg.

2. The use of meloxicam or a pharmacologically acceptable salt thereof according to claim 1, characterised in that no negative effects on renal function occur during a treatment from 13 to 40 months.

3. The use of meloxicam or a pharmacologically acceptable salt thereof according to any one of claims 1 to 2, characterised in that the cats have a pre-existing renal disease.

4. The use of meloxicam or a pharmacologically acceptable salt thereof according to any one of claims 1 to 2, characterised in that the cats have no pre-existing renal disease.

5. The use of meloxicam or a pharmacologically acceptable salt thereof according to any one of claims 1 to 3, characterised in that the cats have a chronic kidney disease.

~~6. The use of meloxicam or a pharmacologically acceptable salt thereof according to any one of claims 1 to 5, characterised in that the daily dose is from 0.01 and 0.075 mg/kg.~~

~~7. The use of meloxicam or a pharmacologically acceptable salt thereof according to any one of claims 1 to 6, characterised in that the daily dose is from 0.02 to 0.06 mg/kg.~~

~~8.~~6. The use of meloxicam or a pharmacologically acceptable salt thereof according to any one of claims 1 to ~~7~~5, characterised in that the daily dose is 0.05 mg/kg.

~~9.~~7. The use of meloxicam or a pharmacologically acceptable salt thereof according to any one of claims 1 to ~~8~~6, characterised in that the musculoskeletal disease is osteoarthritis.

~~10.~~8. The use of meloxicam or a pharmacologically acceptable salt thereof according to any one of claims 1 to ~~9~~7, characterised in that the musculoskeletal disease is a chronic disease.

~~11.~~9. The use of a formulation containing meloxicam or a pharmacologically acceptable salt thereof and one or more vehicles for the manufacture of a medicament for the long-term treatment of musculoskeletal disorders in cats, characterised in that the treatment occurs over a long-term period of from 13 to 40 months and in that the daily dose of from 0.05 to 0.075 mg/kg.

~~12.~~10. The use of the formulation according to claim ~~11~~9, characterised in that no negative effects on renal function occur during a treatment from 13 to 40 months.

~~13.~~11. The use of the formulation according to any one of claims ~~11~~–9 to ~~12~~10, characterised in that it contains or essentially consists of meloxicam salt, water, optionally one or more additives selected from the group consisting of buffers, solubilizers, preservatives and optionally thickeners.